Food
and Drug Administration (FDA)
Center for Drug Evaluation and
Research (CDER)
and
the FDA Pediatric Advisory Committee
Questions and Issues
Questions/Issues for
which FDA would like committee discussion and feedback:
1. Please comment on our approach to classification of
the possible cases of suicidality (suicidal thinking and/or behaviors) and our
analyses of the resulting data from the 23 + 1 pediatric trials involving 9
antidepressant drugs.
2. Do the suicidality data from these trials support the
conclusion that any or all of these drugs increase the risk of suicidality in
pediatric patients?
3. If the answer to the previous question is yes, to
which of these 9 drugs does this increased risk of suicidality apply?
–
Please discuss,
for example, whether the increased risk applies to all antidepressants, only
certain classes of antidepressants, or only certain antidepressants.
4. If there is a class suicidality risk, or a suicidality
risk that is limited to certain drugs in this class, how should this
information be reflected in the labeling of each of
the products?
–
What, if any,
additional regulatory actions should the Agency take?
5. Please discuss what additional research is needed to
further delineate the risks and benefits of these drugs in pediatric patients
with psychiatric illness.